Jackson Tai

Provides brokerage services

Blank check company

Operates a gift store

Develops target-specific small molecule drugs to treat cancer metastasis

Provides leadership advisory and executive search services

Organizes and performs opera shows

Operates as a holding company that provides institutional and consumer banking, wealth management & treasury services

CPP Investments actively buy and sell public and private investments to build a diversified global portfolio that maximizes long-term returns. The firm invests across all major asset classes: public equities, private equities, real estate, infrastructure and fixed income instruments.

Provides passenger and cargo air transportation services

Designs, develops and markets well-being and healthy lifestyle products

Provides banking, insurance and investment banking services

Provides commercial banking and investment advisory services

Provides banking and financial services

Provides security brokerage services

Functions as a College/University

Provides live theatrical presentations

Operates as financial market that provides trading solutions for businesses

Provides grant making services

Operates as a payment technology company

Operates commercialize bank

Operates museum

Develops software applications

Provides telecommunication services

Engages in operation of museums to preserve cultural heritage development

Provides smart card innovation and technology services

Merlin USA is a non-profit company based in Washington, DC.

Functions as a College/University

Engages in discovery, development and manufacturing of biologics

Develops autonomous driving technology

Seed Therapeutics, Inc. is a biotechnology company pioneering the development of first-in-class molecular glue degraders to target disease-causing proteins traditionally considered undruggable. The company is based in King of Prussia, PA. Utilizing their proprietary RITE3™ platform, Seed Therapeutics accesses the full spectrum of over 600 human E3 ligases to design precise targeted protein degradation therapies. The company's lead candidate, ST-01156, an orally administered, brain-penetrant RBM39 degrader, is in phase 1 clinical trials for cancers including Ewing sarcoma and hepatocellular carcinoma, demonstrating potent tumor regression in preclinical models. Beyond oncology, the company advances programs in neurodegeneration, such as oral tau degraders targeting pathological protein aggregation in Alzheimer’s disease. Seed Therapeutics integrates structural biology, molecular modeling, and proteomics to create treatments addressing unmet medical needs with high specificity and minimal off-target effects. The company collaborates with industry leaders and emphasizes rigorous clinical translation to transform scientific insights into precision medicines for cancer, neurological disorders, and immunology. The company was founded by Avram Hershko, Lan Huang, Michele Pagano, Ning Zheng. The CEO is Lan Huang.